^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    COMPANY:
    Atlanpole Biotherapies

    i
    Other names: VitaDX | Atlanpole Biotherapies | VitaDX International
    Related tests:
    Evidence

    News

    4ms
    Avero Diagnostics and VitaDX International announce the signing of a strategic partnership for the distribution in the United States of Visiocyt® Bladder, a diagnostic test for bladder (Atlanpole Bio Press Release)
    "Avero Diagnostics...and VitaDX International...are delighted to announce the signing of a strategic partnership aimed at deploying the VisioCyt® solution. Bladder throughout the United States...The VisioCyt® Bladder solution will be available in the United States early in the first quarter of 2025."
    Licensing / partnership
    |
    VisioCyt®
    over1year
    VitaDX signs a strategic partnership with the XPath group for the use of its VisioCyt® software solution (Atlanpole Bio Press Release)
    "VitaDX...announces its collaboration with XPath to continue the deployment in France of its VisioCyt® solution for the early diagnosis of cervical cancer. the bladder, the 5th most common cancer in France, with more than 13,000 new cases per year...By fully integrating into the patient's care pathway and the logistics of pathological anatomy and cytology practices, the VisioCyt® solution makes it possible, from a simple urine sample, to obtain a rapid result while significantly improving diagnostic performance."
    Licensing / partnership
    |
    VisioCyt®
    almost2years
    VitaDX and MEDIPATH collaborate to deploy VisioCyt®, an innovative solution for the early diagnosis of bladder cancer (Atlanpole Bio Press Release)
    "VitaDX...announces its collaboration with MEDIPATH...to deploy VisioCyt®, a solution for the early diagnosis of bladder cancer, the 5th most common cancer in France...This tool allows an accelerated morphological analysis of all cells present on a digitized urine cytology, in a reliable and reproducible way...It relies on artificial intelligence (machine learning and deep learning) and image processing to facilitate the early detection of bladder cancer."
    Licensing / partnership
    |
    VisioCyt®